Time course changes in signaling pathways and protein synthesis in C 2C12 myotubes following AMPK activation by AICAR

American Journal of Physiology - Endocrinology and Metabolism

Volumn 291, Issue 1, 2006, Pages

  Williamson, David L ^a   Bolster, Douglas R ^a   Kimball, Scot R ^a   Jefferson, Leonard S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

5 aminoimidazole 4 carboxamide 1 d ribonucleoside; Eukaryotic elongation factor 2; Extracellular signal regulated protein kinase; Mammalian target of rapamycin; Regulatory associated protein of mammalian target of rapamycin; Tuberin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HAMARTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; S6 KINASE; TUBERIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EUKARYOTIC CELL; MOUSE; MYOTUBE; NONHUMAN; POLYSOME; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN SYNTHESIS; RIBOSOME SUBUNIT; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BLOTTING, WESTERN; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-4G; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE FIBERS; MUSCLE PROTEINS; MUSCLE, SKELETAL; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; RIBONUCLEOTIDES; RIBOSOMAL PROTEIN S6 KINASES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 33745836687     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00566.2005     Document Type: Article

References (60)

1. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, and Gygi SP. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci USA 102: 667-672, 2005.
2. Bolster DR, Crozier SJ, Kimball SR, and Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 277: 23977-23980, 2002.
3. Browne GJ, Finn SG, and Proud CG. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279: 12220-12231, 2004.
4. Browne GJ and Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 24: 2986-2997, 2004.
5. Campo PA, Das S, Hsiang CH, Bui T, Samuel CE, and Straus DS. Translational regulation of cyclin D1 by 15-deoxy-(delta)12,14-prostaglandin J2. Cell Growth Differ 13: 409-420, 2002.
6. Carlberg U, Nilsson A, and Nygard O. Functional properties of phosphorylated elongation factor 2. Eur J Biochem 191: 639-645, 1990.
7. Castro AF, Rebhun JF, Clark GJ, and Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278: 32493-32496, 2003.
8. Chan AY, Soltys CL, Young ME, Proud CG, and Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279: 32771-32779, 2004.
9. Cheng SW, Fryer LG, Carling D, and Shepherd PR. Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279: 15719-15722, 2004.
10. Chiang GG and Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280: 25485-25490, 2005.
11. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, and Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538, 2004.
12. Fukunaga R and Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 16: 1921-1933, 1997.
13. Gautsch TA, Anthony JC, Kimball SR, Paul GL, Layman DK, and Jefferson LS. Availability of eIF-4E regulates skeletal muscle protein synthesis during recovery from exercise. Am J Physiol Cell Physiol 274: C406-C414, 1998.
14. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, and Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280: 32081-32089, 2005.
15. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, and Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189, 2002.
16. Hardie DG. New roles for the LKB1 → AMPK pathway. Curr Opin Cell Biol 17: 167-173, 2005.
17. Hardie DG. The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 117: 5479-5487, 2004.
18. Hardie DG, Scott JW, Pan DA, and Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546: 113-120, 2003.
19. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, and Hardie DG. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271: 27879-27887, 1996.
20. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
21. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud CG, and Rider M. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 419-423, 2002.
22. Inoki K, Li Y, Xu T, and Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834, 2003.
23. Inoki K, Zhu T, and Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
24. Iwami K, Wang JY, Jain R, McCormack S, and Johnson LR. Intestinal ornithine decarboxylase: half-life and regulation by putrescine. Am J Physiol Gastrointest Liver Physiol 258: G308-G315, 1990.
25. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, and Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128, 2004.
26. Kahn BB, Alquier T, Carling D, and Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
27. Kim DH and Sabatini DM. Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 279: 259-270, 2004.
28. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, and Sabatini DM. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002.
29. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, and Sabatini DM. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11: 895-904, 2003.
30. Kimball SR, Horetsky RL, and Jefferson LS. Implication of eIF2B rather than eIF4E in the regulation of global protein synthesis by amino acids in L6 myoblasts. J Biol Chem 273: 30945-30953, 1998.
31. Kimball SR, Horetsky RL, and Jefferson LS. Signal transduction pathways involved in the regulation of protein synthesis by insulin in L6 myoblasts. Am J Physiol Cell Physiol 274: C221-C228, 1998.
32. Kimball SR, Jurasinki CV, Lawrence JC Jr, and Jefferson LS. Insulin stimulates protein synthesis in skeletal muscle by enhancing the association of eIF-4E and eIF-4G. Am J Physiol Cell Physiol 272: C754-C759, 1997.
33. Kimball SR, Orellana RA, O'Connor PMJ, Suryawan A, Bush JA, Nguyen HV, Thivierge MC, Jefferson LS, and Davis TA. Endotoxin induces differential regulation of mTOR-dependent signaling in skeletal muscle and liver of neonatal pigs. Am J Physiol Endocrinol Metab 285: E637-E644, 2003.
34. Knebel A, Morrice N, and Cohen P. A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta. EMBO J 20: 4360-4369, 2001.
35. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, and Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol 15: 702-713, 2005.
36. Loreni F, Thomas G, and Amaldi F. Transcription inhibitors stimulate translation of 5′ TOP mRNAs through activation of S6 kinase and the mTOR/FRAP signalling pathway. Eur J Biochem 267: 6594-6601, 2000.
37. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, and Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193, 2005.
38. Merrick WC. Cap-dependent and cap-independent translation in eukaryotic systems. Gene 332: 1-11, 2004.
39. Nairn AC and Palfrey HC. Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2. J Biol Chem 262: 17299-17303, 1987.
40. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, and Yonezawa K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278: 15461-15464, 2003.
41. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J, and Yonezawa K. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9: 359-366, 2004.
42. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, and Thomas G. S6K1-/-/S6K2-/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124, 2004.
43. Potter CJ, Pedraza LG, and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4: 658-665, 2002.
44. Reiter AK, Bolster DR, Crozier SJ, Kimball SR, and Jefferson LS. Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. Am J Physiol Endocrinol Metab 288: E980-E988, 2005.
45. Rennie MJ and Tipton KD. Protein and amino acid metabolism during and after exercise and the effects of nutrition. Annu Rev Nutr 20: 457-483, 2000.
46. Rolfe DF and Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 77: 731-758, 1997.
47. Rolfe M, McLeod LE, Pratt PF, and Proud CG. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 388: 973-984, 2005.
48. Roux PP, Ballif BA, Anjum R, Gygi SP, and Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101: 13489-13494, 2004.
49. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
50. Schalm SS, Fingar DC, Sabatini DM, and Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13: 797-806, 2003.
51. Schalm SS, Tee AR, and Blenis J. Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation. J Biol Chem 280: 11101-11106, 2005.
52. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, and Cantley LC. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99, 2004.
53. Sonenberg N. mRNA 5′ cap-binding protein eIF4E and control of cell growth. In: Translational Control, edited by Hershey JWB, Mathews MB, and Sonenberg N. Cold Spring Harbor, IL: Cold Spring Harbor Laboratory Press, 1996, p. 245-269.
54. Stolovich M, Tang H, Hornstein E, Levy G, Cohen R, Bae SS, Birnbaum MJ, and Meyuhas O. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol 22: 8101-8113, 2002.
55. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, and Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 353: 33-36, 1994.
56. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, and Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99: 13571-13576, 2002.
57. Thomson DM and Gordon SE. Diminished overload-induced hypertrophy in aged fast-twitch skeletal muscle is associated with AMPK hyperphosphorylation. J Appl Physiol 98: 557-564, 2005.
58. Wang X, Li W, Williams M, Terada N, Alessi DR, and Proud CG. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20: 4370-4379, 2001.
59. Waskiewicz AJ, Flynn A, Proud CG, and Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16: 1909-1920, 1997.
60. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, and Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578-581, 2003.